ArticleCancer biology & therapy2024

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.

Hongjie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.